Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. France
  4. Euronext Paris
  5. Biophytis S.A.
  6. News
  7. Summary
    ALBPS   FR0012816825

BIOPHYTIS S.A.

(ALBPS)
  Report
SummaryQuotesChartsNewsCalendarCompanyFinancials 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Biophytis SA Announces Top Line Results of the SARA-INT Phase 2 Clinical Study with Sarconeos in Sarcopenia

08/02/2021 | 02:00am EDT

Biophytis SA announced the top line results of the SARA-INT phase 2 clinical study with Sarconeos (BIO101) in Sarcopenia: The effect of two doses of Sarconeos (BIO101), 175 mg bid and 350 mg bid, have been compared to placebo on gait speed as measured by the 400-Meter Walk Test (400 MWT), the primary end-point of the study, in the Full Analysis Dataset (FAS) and in the Per-Protocol population (PP, subset of participants that complied to the clinical protocol). Efficacy - Sarconeos (BIO101) at the highest dose of 350 mg bid showed a clinically meaningful improvement compared to placebo in gait speed, as measured in the 400MWT after 6 months of treatment, of 0.09 m/s in the FAS population and 0.10 m/s in the PP population (treatment effect significant, p 65 years old), low Appendicular Lean Mass (ALM) adjusted by Body-Mass Index (BMI) combined with reduced mobility assessed by the Short Physical Performance Battery index (SPPB = 8). Efficacy was evaluated based on the gait speed from the 400-Meter Walk Test (400MWT) as the primary endpoint, in the Full Analysis Set population (FAS, all randomized participants ie 233 participants) and in the Per-Protocol population (PP, subset of participants that complied to the clinical protocol ie 152 participants). Handgrip strength and Patient-Reported Outcome (PRO) of mobility capacity as measured with the SF-36 questionnaire are key secondary endpoints.


© S&P Capital IQ 2021
All news about BIOPHYTIS S.A.
11:12aBIOPHYTIS S A : reports H1 2021 financial results and provides business update (..
PU
02:01aBiophytis Reports H1 2021 Financial Results and Provides Business Update
GL
09/15BIOPHYTIS S A : announces DMC second interim analysis efficacy results in the pr..
PU
09/15GLOBAL MARKETS LIVE : Microsoft, Apple, The Boeing Company, AT&T, Activision Bli..
09/15BIOPHYTIS : Says Data Monitoring Committee Recommends Continuation of COVID-19 D..
MT
09/15Biophytis Announces DMC Second Interim Analysis Efficacy Results in the Promi..
GL
09/15Biophytis SA Announces DMC Second Interim Analysis Efficacy Results in the Pr..
CI
09/14BIOPHYTIS : to Attend Key Upcoming Investor Events and Industry Conferences
AQ
09/09BIOPHYTIS : Names New Chief Medical Officer
MT
09/09BIOPHYTIS S A : Appoints New Chief Medical Officer
MT
More news
Financials
Sales 2020 - - -
Net income 2020 -17,1 M -20,0 M -20,0 M
Net cash 2020 9,25 M 10,8 M 10,8 M
P/E ratio 2020 -3,24x
Yield 2020 -
Capitalization 87,7 M 103 M 103 M
EV / Sales 2019 -
EV / Sales 2020 -
Nbr of Employees 25
Free-Float 21,7%
Chart BIOPHYTIS S.A.
Duration : Period :
Biophytis S.A. Technical Analysis Chart | ALBPS | FR0012816825 | MarketScreener
Technical analysis trends BIOPHYTIS S.A.
Short TermMid-TermLong Term
TrendsNeutralBearishNeutral
Income Statement Evolution
Managers and Directors
Stanislas Veillet Chairman & Chief Executive Officer
Evelyne Nguyen Chief Financial Officer
Pierre J. Dilda Chief Scientific Officer
Rob van Maanen Chief Medical Officer
Waly Dioh Chief Operating Officer
Sector and Competitors
1st jan.Capi. (M$)
BIOPHYTIS S.A.-21.61%104
BIONTECH SE357.13%90 003
GILEAD SCIENCES, INC.22.43%89 434
REGENERON PHARMACEUTICALS35.20%67 910
WUXI APPTEC CO., LTD.35.75%65 728
VERTEX PHARMACEUTICALS-20.83%48 539